Navigation Links
Progenics and Wyeth Announce Positive Results from Three-Month,Clinical-Extension Study of Subcutaneous Methylnaltrexone for the,Treatment of Opioid-Induced Constipation in Patients with Advanced,Illness

TARRYTOWN, N.Y. & MADISON, N.J.--(BUSINESS WIRE)--Jun 28, 2007 - Progenics Pharmaceuticals, Inc. (NASDAQ: PGNX) and Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), today announced positive results from a three-month open-label extension study of subcutaneous methylnaltrexone for the treatment of opioid-induced constipation (OIC) in patients with advanced illness. The results are scheduled to be presented at the Multinational Association of Supportive Care in Cancer (MASCC) Symposium in St. Gallen, Switzerland.

Eighty-two OIC patients completed a placebo-controlled phase 3 study (MNTX 302), and then participated in the three-month open-label extension study of subcutaneous methylnaltrexone. The goal of the extension study was to obtain efficacy and safety data on subcutaneous methylnaltrexone, administered as needed, for up to three months.

Forty-two OIC patients received subcutaneous methylnaltrexone previously in the double-blind MNTX 302 study, and then entered this open-label extension study. For these forty-two patients, the mean laxation response rates (laxation within four hours) were 45.5% during the first month, 57.7% in the second month, and 57.3% in the third and final month. For the remaining forty patients who had first received placebo in the double-blind MNTX 302 study prior to entering this open-label extension study, laxation response rates were 48.3% during the first month, 47.6% in the second month, and 52.1% in the third and final month. Consistent with previous studies, subcutaneous methylnaltrexone was generally well-tolerated in the three-month open-label study, and the most common adverse event reported was abdominal pain which was typically mild-to-moderate in severity.

"These results show that methylnaltrexone, when administered subcutaneously for up to three months, continued to induce laxation in advanced illness patients with OIC," commented Paul J. Maddon,
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. Progenics Announces Positive Results in Clinical Trial of Novel HIV Therapy
2. Wyeth Presents Phase 3 Data for Pristiq, an Investigational Non-Hormonal Therapy for Menopausal Hot Flashes and Night Sweats
3. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
4. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
5. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
6. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
7. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
8. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
9. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
10. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
11. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
Post Your Comments:
(Date:9/19/2014)... , September 19, 2014 ... IQ den äußerst erfolgreichen Serialisierungs-Countdown-Kalender aktualisiert, der jetzt ... interaktive PDF, verfügbar unter pharmaserialisation.com , zeigt ... sie jeweils in Kraft treten. Für ... nicht länger um das "ob", sondern darum, "wann" ...
(Date:9/19/2014)... VIENNA , Sept. 19, 2014 ... positive interim clinical data for its lead candidate ITCA ... diabetes patients with high baseline HbA1c levels at the ... for the Study of Diabetes (EASD). Data from the ... reduced levels of blood sugar in patients with poorly ...
(Date:9/19/2014)... Mass. , Sept. 19, 2014   Personal ... advanced cancer genome analysis and testing services, and ... and developing highly selective kinase inhibitors for genomically ... study of malignant mixed Mullerian tumors (MMMT), an ... system, also known as carcinosarcoma. The new ...
Breaking Medicine Technology:Pharma IQ stellt weltweite Serialisierungsfristen in seinen Countdown-Kalender 2014 - 2018 2Intarcia Announces Presentation of Phase 3 Data at EASD Showing ITCA 650 Markedly Reduces Blood Sugar In Patients With Poorly Controlled Type 2 Diabetes 2Intarcia Announces Presentation of Phase 3 Data at EASD Showing ITCA 650 Markedly Reduces Blood Sugar In Patients With Poorly Controlled Type 2 Diabetes 3Intarcia Announces Presentation of Phase 3 Data at EASD Showing ITCA 650 Markedly Reduces Blood Sugar In Patients With Poorly Controlled Type 2 Diabetes 4First Discovery Of Actionable Genetic Alterations In A Deadly Cancer Reported By Personal Genome Diagnostics And Blueprint Medicines 2First Discovery Of Actionable Genetic Alterations In A Deadly Cancer Reported By Personal Genome Diagnostics And Blueprint Medicines 3First Discovery Of Actionable Genetic Alterations In A Deadly Cancer Reported By Personal Genome Diagnostics And Blueprint Medicines 4
... 2011 Seal Shield LLC today announced ... for the iPad.  The product has been designed specifically ... use in hospital settings. The Seal Shield ... which is resistant to liquids including blood and bleach. ...
... MALVERN, Pa., Feb. 21, 2011 Today, Siemens (NYSE: ... Overhage, MD, PhD, as Chief Medical Informatics Officer (CMIO), of ... of the In diana Health Information Exchange ... this not-for-profit organization. In his role at Siemens, Marc will ...
Cached Medicine Technology:Siemens Appoints Overhage as New Chief Medical Informatics Officer 2
(Date:9/19/2014)... of human cancers have abnormally upregulated chemical signals ... are controlled during tumor formation is not fully ... Fayngerts, PhD, both researchers in the department of ... of Medicine, University of Pennsylvania, and colleagues report ... cancer by targeting these pathways. , Lipid second ...
(Date:9/19/2014)... NJ (PRWEB) September 19, 2014 ... not-for-profit provider of home health care, hospice and palliative ... Bank to ring the Opening Bell yesterday at the ... a New Jersey philanthropist and social entrepreneur to care ... VNA Health Group has always worked to meet the ...
(Date:9/19/2014)... (HealthDay News) -- U.S. military troops deployed to sunny ... according to a new study. Many returning ... In some cases, military personnel developed blisters on their ... or size of their moles since being deployed overseas. ... for skin cancer, the study authors noted. "The ...
(Date:9/19/2014)... 2014 (HealthDay News) -- Although there is mounting ... most middle-aged and older adults in the United ... according to new research. Less than one-quarter ... set by the Department of Health and Human ... essential for promoting health and fitness and staying ...
(Date:9/19/2014)... The Alliance for Bangladesh Worker ... National Fire Protection Association (NFPA), a recognized international ... in a Memorandum of Understanding signed by both ... other stakeholders with information, guidance and access to ... and safety of workers in ready-made garment (RMG) ...
Breaking Medicine News(10 mins):Health News:New cancer drug target involving lipid chemical messengers 2Health News:NJ Largest Home Healthcare Not-for-Profit Joins Deutsche Bank to Ring NYSE Opening Bell 2Health News:NJ Largest Home Healthcare Not-for-Profit Joins Deutsche Bank to Ring NYSE Opening Bell 3Health News:Some U.S. Troops May Face Greater Skin Cancer Risk 2Health News:Adults Over 45 Not Meeting U.S. Muscle Strengthening Guidelines, Study Says 2Health News:Alliance for Bangladesh Worker Safety and NFPA Sign Memorandum of Understanding to Strengthen Safety in Bangladesh Garment Factories 2Health News:Alliance for Bangladesh Worker Safety and NFPA Sign Memorandum of Understanding to Strengthen Safety in Bangladesh Garment Factories 3
... June 22 With the outbreak of H1N1 influenza in ... vaccine, which can effectively prevent the disease from spreading. The ... become a hot topic around the world. In fact, the ... industry in China and globally for quite some time now. ...
... Families by Killing 99.9% of Illness-Causing Bacteria on Soft Surfaces , ... be the only ones getting comfy and cozy on the sofa. ... home can harbor thousands of bacteria. In fact, if fabric ... on them for months.(1) , , Families now have ...
... has found that Caucasians are much more likely than people ... soft tissue cancer called Ewing,s sarcoma. In addition, among Caucasians ... women. Published in the August 1, 2009 issue of ... the study indicates that examining the gender and racial differences ...
... - Donating blood today will help save lives , ... and its divisions in Manhattan, Long Island, Hudson Valley, Brooklyn / ... donate blood in advance of the July 4th holiday weekend. ... "trauma season" for most emergency rooms. According to the Centers ...
... transplant recipients to suppress their immune systems, has a paradoxical ... Emory Vaccine Center have discovered. In experiments conducted in ... memory CD8 T cells, which enable the immune system to ... second encounter. The results were published online ahead of ...
... Pick shades with UV protection, and wear them a ... News) -- Price and style -- not protection from ... considerations when buying sunglasses, a new survey has found. ... the American Optometric Association, which conducted the survey. , ...
Cached Medicine News:Health News:Frost & Sullivan Sees Opportunities in Chinese Vaccine Industry 2Health News:Frost & Sullivan Sees Opportunities in Chinese Vaccine Industry 3Health News:Harmful Bacteria May Hide on Soft Surfaces in Your Home 2Health News:Caucasians are at higher risk of developing Ewing's sarcoma than other races 2Health News:Give Life for the Fourth of July 2Health News:Give Life for the Fourth of July 3Health News:Transplant drug stimulates immune memory 2Health News:Not All Sunglasses Are Created Equal 2
... range of Milli-Q ultrapure water systems ... requirements. Each of the five new ... target contaminants detrimental to particular applications ... ICP-MS. The systems incorporate a high ...
... has developed a range of Milli-Q ... specific water quality requirements. Each of ... designed to specifically target contaminants detrimental ... molecular biology and ICP-MS. The systems ...
... range of Milli-Q ultrapure water systems ... requirements. Each of the five new ... target contaminants detrimental to particular applications ... ICP-MS. The systems incorporate a high ...
... a range of Milli-Q ultrapure water ... quality requirements. Each of the five ... specifically target contaminants detrimental to particular ... and ICP-MS. The systems incorporate a ...
Medicine Products: